The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins

Human Molecular Genetics

Volumn 24, Issue 15, 2015, Pages 4250-4267

  Moehle, Mark S ^a   Daher, João Paulo Lima ^a   Hull, Travis D ^b   Boddu, Ravindra ^c   Abdelmotilib, Hisham A ^a   Mobley, James ^b   Kannarkat, George T ^d   Tansey, Malú G ^d   West, Andrew B ^a  

^a The University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c University of Alabama at Birmingham   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; FLUCONAZOLE; LIPOPOLYSACCHARIDE; NERVE GROWTH FACTOR; PHOSPHOTRANSFERASE INHIBITOR; REGULATOR PROTEIN; ROVAZOLAC; THIOGLYCOLIC ACID; ACTIN; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, RAT; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; BLOOD BRAIN BARRIER; BONE MARROW CELL; CHEMOTAXIS; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G2019S LRRK2 MUTATION; GENE MUTATION; GENE ONTOLOGY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPO SIGNALING; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; MASS SPECTROMETRY; MOUSE; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PERITONEUM; PHAGOCYTOSIS; POLYADENYLATION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SOCIAL BEHAVIOR; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; RAT; SUBSTANTIA NIGRA;

ACTINS; ANIMALS; CHEMOTAXIS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MUTATION; MYELOID CELLS; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RATS; SUBSTANTIA NIGRA;

EID: 85018214550     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv157     Document Type: Article

References (133)

1. Bosgraaf, L. and Van Haastert, P.J. (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta., 1643, 5–10.
2. Van Limbergen, J., Wilson, D.C. and Satsangi, J. (2009) The genetics of Crohn’s disease. Annu. Rev. Genomics Hum. Genet., 10, 89–116.
3. Zhang, F.R., Huang, W., Chen, S.M., Sun, L.D., Liu, H., Li, Y., Cui, Y., Yan, X.X., Yang, H.T., Yang, R.D. et al. (2009) Genome-wide association study of leprosy. N. Engl. J. Med., 361, 2609–2618.
4. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601–607.
5. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 44, 595–600.
6. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat. Genet., 41, 1303–1307.
7. Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M. et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet., 46, 989–993.
8. West, A.B. (2014) Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov. Disord., 30, 180–189.
9. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA, 102, 16842–16847.
10. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587–593.
11. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S.L., Solanoy, H.O., Drummond, J., Zhang, X., Ding, X. et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of pd mutations. Sci. Trans. Med., 4, 1–12.
12. Stafa, K., Trancikova, A., Webber, P.J., Glauser, L., West, A.B. and Moore, D.J. (2012) GTPase activity and neuronal toxicity of Parkinson’s disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet., 8, e1002526.
13. Nichols, R.J., Dzamko, N., Morrice, N.A., Campbell, D.G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A.R. et al. (2010) 14–3–3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem. J., 430, 393–404.
14. MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B.D., Marder, K.S., Honig, L.S., Clark, L.N., Small, S.A. et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron, 77, 425–439.
15. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231–1233.
16. Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A. B., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA, 102, 18676–18681.
17. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 23, 329–341.
18. Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S. and West, A.B. (2014) Abrogation of alpha-synucleinmediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl Acad. Sci. USA, 111, 9289–9294.
19. Gardet, A., Benita, Y., Li, C., Sands, B.E., Ballester, I., Stevens, C., Korzenik, J.R., Rioux, J.D., Daly, M.J., Xavier, R.J. et al. (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol., 185, 5577–5585.
20. Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R.F., Tong, Y., Kabbach, G., Venderova, K., Girardin, S.E., Bulman, D.E., Scherzer, C.R. et al. (2011) Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neural. Transm., 118, 795–808.
21. Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M. and West, A.B. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci., 32, 1602–1611.
22. Thevenet, J., Pescini Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C. and Sagot, Y.J. (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One, 6, e21519.
23. Alvarez-Errico, D., Vento-Tormo, R., Sieweke, M. and Ballestar, E. (2014) Epigenetic control of myeloid cell differentiation, identity and function. Nat. Rev. Immunol., 15, 7–17.
24. Chistiakov, D.A., Sobenin, I.A., Orekhov, A.N. and Bobryshev, Y.V. (2015) Myeloid dendritic cells: development, functions, and role in atherosclerotic inflammation. Immunobiology, 14, 279–284.
25. Crook, K.R. and Liu, P. (2014) Role of myeloid-derived suppressor cells in autoimmune disease. World J. Immunol., 4, 26–33.
26. Kim, B., Yang, M.S., Choi, D., Kim, J.H., Kim, H.S., Seol, W., Choi, S., Jou, I., Kim, E.Y. and Joe, E.H. (2012) Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One, 7, e34693.
27. Marker, D.F., Puccini, J.M., Mockus, T.E., Barbieri, J., Lu, S.M. and Gelbard, H.A. (2012) LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J. Neuroinflammation, 9, 261.
28. Caesar, M., Zach, S., Carlson, C.B., Brockmann, K., Gasser, T. and Gillardon, F. (2013) Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol. Dis., 54, 280–288.
29. Bosgraaf, L., Waijer, A., Engel, R., Visser, A.J., Wessels, D., Soll, D. and van Haastert, P.J. (2005) RasGEF-containing proteins GbpC and GbpD have differential effects on cell polarity and chemotaxis in Dictyostelium. J. Cell Sci., 118, 1899–1910.
30. Cha, I., Lee, S.H. and Jeon, T.J. (2010) Chemoattractantmediated Rap1 activation requires GPCR/G proteins. Mol. Cells, 30, 563–567.
31. Kicka, S., Shen, Z., Annesley, S.J., Fisher, P.R., Lee, S., Briggs, S. and Firtel, R.A. (2011) The LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin cytoskeleton. Mol. Biol. Cell, 22, 2198–2211.
32. Baptista, M.A., Dave, K.D., Frasier, M.A., Sherer, T.B., Greeley, M., Beck, M.J., Varsho, J.S., Parker, G.A., Moore, C., Churchill, M.J. et al. (2013) Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One, 8, e80705.
33. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S. et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet., 20, 4209–4223.
34. Liu, Z., Galemmo, R.A. Jr, Fraser, K.B., Moehle, M.S., Sen, S., Volpicelli-Daley, L.A., DeLucas, L.J., Ross, L.J., Valiyaveettil, J., Moukha-Chafiq, O. et al. (2014) Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J. Biol. Chem., 289, 32937–32951.
35. Gillardon, F., Schmid, R. and Draheim, H. (2012) Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience, 208, 41–48.
36. Moehle, M.S. and West, A.B. (2014) M1 and M2 immune activation in Parkinson’s Disease: Foe and ally? Neuroscience, 14, 975–980.
37. Martinez, F.O. and Gordon, S. (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep, 6, 13.
38. Castano, A., Herrera, A.J., Cano, J. and Machado, A. (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem., 81, 150–157.
39. Castano, A., Herrera, A.J., Cano, J. and Machado, A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem., 70, 1584–1592.
40. West, A.B., Cowell, R.M., Daher, J.P., Moehle, M.S., Hinkle, K. M., Melrose, H.L., Standaert, D.G. and Volpicelli-Daley, L.A. (2014) Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J. Comp. Neurol., 522, 2465–2480.
41. Kim, W.G., Mohney, R.P., Wilson, B., Jeohn, G.H., Liu, B. and Hong, J.S. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci., 20, 6309–6316.
42. Lee, J.W., Tapias, V., Di Maio, R., Greenamyre, J.T. and Cannon, J.R. (2015) Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol. Aging, 36, 505–518.
43. Walker, M.D., Volta, M., Cataldi, S., Dinelle, K., Beccano-Kelly, D., Munsie, L., Kornelsen, R., Mah, C., Chou, P., Co, K. et al. (2014) Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. J. Parkinsons Dis., 4, 483–498.
44. Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.J., Morais, V. A., Vilain, S., Haddad, D. et al. (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron, 75, 1008–1021.
45. Stafa, K., Tsika, E., Moser, R., Musso, A., Glauser, L., Jones, A., Biskup, S., Xiong, Y., Bandopadhyay, R., Dawson, V.L. et al. (2014) Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin GTPase super-family. Hum. Mol. Genet., 23, 2055–2077.
46. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.W., Savitt, J.M., Waldvogel, H.J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 60, 557–569.
47. Higashi, S., Moore, D.J., Yamamoto, R., Minegishi, M., Sato, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., Hino, H. et al. (2009) Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J. Neuropathol. Exp. Neurol., 68, 994–1005.
48. Orenstein, S.J., Kuo, S.H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L.S., Dauer, W., Consiglio, A. et al. (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci., 16, 394–406.
49. Manzoni, C., Mamais, A., Dihanich, S., Abeti, R., Soutar, M.P., Plun-Favreau, H., Giunti, P., Tooze, S.A., Bandopadhyay, R. and Lewis, P.A. (2013) Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim. Biophys. Acta., 1833, 2900–2910.
50. Alegre-Abarrategui, J., Christian, H., Lufino, M.M., Mutihac, R., Venda, L.L., Ansorge, O. and Wade-Martins, R. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet., 18, 4022–4034.
51. Piccoli, G., Condliffe, S.B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., Meixner, A., Sarioglu, H., Vogt-Weisenhorn, D.M., Wurst, W. et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci., 31, 2225–2237.
52. Luster, A.D., Alon, R. and von Andrian, U.H. (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol., 6, 1182–1190.
53. Honda, S., Sasaki, Y., Ohsawa, K., Imai, Y., Nakamura, Y., Inoue, K. and Kohsaka, S. (2001) Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/ocoupled P2Y receptors. J. Neurosci., 21, 1975–1982.
54. Choi, H.G., Zhang, J., Deng, X., Hatcher, J.M., Patricelli, M.P., Zhao, Z., Alessi, D.R. and Gray, N.S. (2012) Brain penetrant LRRK2 inhibitor. ACS Med. Chem. Lett., 3, 658–662.
55. Gallily, R., Warwick, A. and Bang, F.B. (1964) Effect of cortisone of genetic resistance to mouse heptatitis virus in vivo and in vitro. Proc. Natl Acad. Sci. USA, 51, 1158–1164.
56. Barski, G., Messore, G. and Lepine, P. (1955) Artificial peritoneal exudate, source of cells for virus culture in vitro. Ann. Inst. Pasteur. (Paris), 89, 366–371.
57. Ghosn, E.E., Cassado, A.A., Govoni, G.R., Fukuhara, T., Yang, Y., Monack, D.M., Bortoluci, K.R., Almeida, S.R., Herzenberg, L.A. and Herzenberg, L.A. (2010) Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc. Natl Acad. Sci. USA, 107, 2568–2573.
58. Schleicher, U., Hesse, A. and Bogdan, C. (2005) Minute numbers of contaminant CD8+ T cells or CD11b+CD11c+ NK cells are the source of IFN-gamma in IL-12/IL-18-stimulated mouse macrophage populations. Blood, 105, 1319–1328.
59. Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q.W. and Nathan, C. (1993) Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med., 178, 605–613.
60. Ness, D., Ren, Z., Gardai, S., Sharpnack, D., Johnson, V.J., Brennan, R.J., Brigham, E.F. and Olaharski, A.J. (2013) Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLoS One, 8, e66164.
61. Kigerl, K.A., Gensel, J.C., Ankeny, D.P., Alexander, J.K., Donnelly, D.J. and Popovich, P.G. (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci., 29, 13435–13444.
62. Mikita, J., Dubourdieu-Cassagno, N., Deloire, M.S., Vekris, A., Biran, M., Raffard, G., Brochet, B., Canron, M.H., Franconi, J. M., Boiziau, C. et al. (2011) Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler., 17, 2–15.
63. Mege, J.L., Mehraj, V. and Capo, C. (2011) Macrophage polarization and bacterial infections. Curr. Opin. Infect. Dis., 24, 230–234.
64. Kuziel, W.A., Morgan, S.J., Dawson, T.C., Griffin, S., Smithies, O., Ley, K. and Maeda, N. (1997) Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl Acad. Sci. USA, 94, 12053–12058.
65. Mack, M., Cihak, J., Simonis, C., Luckow, B., Proudfoot, A.E., Plachy, J., Bruhl, H., Frink, M., Anders, H.J., Vielhauer, V. et al. (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol., 166, 4697–4704.
66. Mildner, A., Mack, M., Schmidt, H., Brück, W., Djukic, M., Zabel, M.D., Hille, A., Priller, J. and Prinz, M. (2009) CCR2 +Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain, 132, 2487–2500.
67. Kuziel, W.A., Dawson, T.C., Quinones, M., Garavito, E., Chenaux, G., Ahuja, S.S., Reddick, R.L. and Maeda, N. (2003) CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis, 167, 25–32.
68. Meixner, A., Boldt, K., Van Troys, M., Askenazi, M., Gloeckner, C.J., Bauer, M., Marto, J.A., Ampe, C., Kinkl, N. and Ueffing, M. (2011) A QUICK screen for Lrrk2 interaction partners–leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell Proteomics, 10, 1–17.
69. Caesar, M., Felk, S., Aasly, J.O. and Gillardon, F. (2015) Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers. Neuroscience, 284, 311–324.
70. Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.L., Long, C.X., Lobbestael, E., Baekelandt, V., Taymans, J.M., Sun, L. et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci., 29, 13971–13980.
71. Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.P., St-Denis, N.A., Li, T., Miteva, Y.V., Hauri, S., Sardiu, M.E., Low, T. Y. et al. (2013) The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods, 10, 730–736.
72. Henderson, J.L., Kormos, B.L., Hayward, M.M., Coffman, K.J., Jasti, J., Kurumbail, R.G., Wager, T.T., Verhoest, P.R., Noell, G. S., Chen, Y. et al. (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]ben-zonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J. Med. Chem., 58, 419–432.
73. Jones, G.E. (2000) Cellular signaling in macrophage migration and chemotaxis. J. Leukocyte Biol., 68, 593–602.
74. Mukai, Y., Iwaya, K., Ogawa, H. and Mukai, K. (2005) Involvement of Arp2/3 complex in MCP-1-induced chemotaxis. Biochem. Biophys. Res. Commun., 334, 395–402.
75. Baumann, K. (2012) Cell migration: Chemotaxis without ARP2/3. Nat. Rev. Mol. Cell Biol., 13, 211–211.
76. Choi, C.-H., Thomason, P.A., Zaki, M., Insall, R.H. and Barber, D.L. (2012) Phosphorylation of actin-related protein 2 (Arp2) is required for normal development and cAMP chemotaxis in Dictyostelium. J. Biol. Chem., 4, 2464–2474.
77. Cavnar, P.J., Mogen, K., Berthier, E., Beebe, D.J. and Huttenlocher, A. (2012) The actin regulatory protein HS1 interacts with Arp2/3 and mediates efficient neutrophil chemotaxis. J. Biol. Chem., 287, 25466–25477.
78. Wu, C., Asokan, S.B., Berginski, M.E., Haynes, E.M., Sharp-less, N.E., Griffith, J.D., Gomez, S.M. and Bear, J.E. (2012) Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell, 148, 973–987.
79. Asokan, S.B., Johnson, H.E., Rahman, A., King, S.J., Rotty, J.D., Lebedeva, I.P., Haugh, J.M. and Bear, J.E. (2014) Mesenchymal chemotaxis requires selective inactivation of myosin II at the leading edge via a noncanonical PLCγ/PKCα pathway. Dev. Cell, 31, 747–760.
80. Rey, M., Vicente-Manzanares, M., Viedma, F., Yanez-Mo, M., Urzainqui, A., Barreiro, O., Vazquez, J. and Sanchez-Madrid, F. (2002) Cutting edge: association of the motor protein nonmuscle myosin heavy chain-IIA with the C terminus of the chemokine receptor CXCR4 in T lymphocytes. J. Immunol., 169, 5410–5414.
81. Sandquist, J.C., Swenson, K.I., Demali, K.A., Burridge, K. and Means, A.R. (2006) Rho kinase differentially regulates phosphorylation of nonmuscle myosin II isoforms A and B during cell rounding and migration. J. Biol. Chem., 281, 35873–35883.
82. Kim, S.V., Mehal, W.Z., Dong, X., Heinrich, V., Pypaert, M., Mellman, I., Dembo, M., Mooseker, M.S., Wu, D. and Flavell, R.A. (2006) Modulation of cell adhesion and motility in the immune system by Myo1f. Science, 314, 136–139.
83. Even-Ram, S., Doyle, A.D., Conti, M.A., Matsumoto, K., Adelstein, R.S. and Yamada, K.M. (2007) Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk. Nat. Cell Biol., 9, 299–309.
84. Dulyaninova, N.G., House, R.P., Betapudi, V. and Bresnick, A. R. (2007) Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells. Mol. Biol. Cell, 18, 3144–3155.
85. Vicente-Manzanares, M., Zareno, J., Whitmore, L., Choi, C.K. and Horwitz, A.F. (2007) Regulation of protrusion, adhesion dynamics, and polarity by myosins IIA and IIB in migrating cells. J. Cell Biol., 176, 573–580.
86. Sandquist, J.C. and Means, A.R. (2008) The C-terminal tail region of nonmuscle myosin II directs isoform-specific distribution in migrating cells. Mol. Biol. Cell, 19, 5156–5167.
87. Chen, C.L., Wang, Y., Sesaki, H. and Iijima, M. (2012) Myosin I links PIP3 signaling to remodeling of the actin cytoskeleton in chemotaxis. Sci. Signal, 5, 209.
88. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem. J., 405, 307–317.
89. Beilina, A., Rudenko, I.N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S.K., Kalia, L.V., Lobbestael, E., Chia, R., Ndukwe, K. et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl Acad. Sci. USA, 111, 2626–2631.
90. Schreij, A.M., Chaineau, M., Ruan, W., Lin, S., Barker, P.A., Fon, E.A. and McPherson, P.S. (2015) LRRK2 localizes to endosomes and interacts with clathrin-light chains to limit Rac1 activation. EMBO Rep., 16, 79–86.
91. Habig, K., Gellhaar, S., Heim, B., Djuric, V., Giesert, F., Wurst, W., Walter, C., Hentrich, T., Riess, O. and Bonin, M. (2013) LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and tropomyosin 4. Biochim. Biophys. Acta., 1832, 2352–2367.
92. Bosgraaf, L., Russcher, H., Smith, J.L., Wessels, D., Soll, D.R. and Van Haastert, P.J. (2002) A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium. EMBO J., 21, 4560–4570.
93. Rougerie, P., Miskolci, V. and Cox, D. (2013) Generation of membrane structures during phagocytosis and chemotaxis of macrophages: role and regulation of the actin cytoskeleton. Immunol. Rev., 256, 222–239.
94. Pecci, A., Bozzi, V., Panza, E., Barozzi, S., Gruppi, C., Seri, M. and Balduini, C.L. (2011) Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells. Thromb. Haemost., 106, 693–704.
95. Jacobelli, J., Bennett, F.C., Pandurangi, P., Tooley, A.J. and Krummel, M.F. (2009) Myosin-IIA and ICAM-1 regulate the interchange between two distinct modes of T cell migration. J. Immunol., 182, 2041–2050.
96. Fraser, K.B., Moehle, M.S., Daher, J.P., Webber, P.J., Williams, J.Y., Stewart, C.A., Yacoubian, T.A., Cowell, R.M., Dokland, T., Ye, T. et al. (2013) LRRK2 secretion in exosomes is regulated by 14–3–3. Hum. Mol. Genet., 22, 4988–5000.
97. Sartor, R.B. (2006) Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol., 3, 390–407.
98. Marks, D.J. and Segal, A.W. (2008) Innate immunity in inflammatory bowel disease: a disease hypothesis. J. Pathol., 214, 260–266.
99. Marks, D.J., Harbord, M.W., MacAllister, R., Rahman, F.Z., Young, J., Al-Lazikani, B., Lees, W., Novelli, M., Bloom, S. and Segal, A.W. (2006) Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet, 367, 668–678.
100. Dessein, R., Chamaillard, M. and Danese, S. (2008) Innate immunity in Crohn’s disease: the reverse side of the medal. J. Clin. Gastroenterol., 42, 144–147.
101. Hagge, D.A., Ray, N.A., Krahenbuhl, J.L. and Adams, L.B. (2004) An in vitro model for the lepromatous leprosy granuloma: fate of mycobacterium leprae from target macrophages after interaction with normal and activated effector macrophages. J. Immunol., 172, 7771–7779.
102. Turk, J.L. (1985) The mononuclear phagocyte system in granulomas. Br. J. Dermatol., 113, 49–54.
103. Adams, L.B., Scollard, D.M., Ray, N.A., Cooper, A.M., Frank, A. A., Orme, I.M. and Krahenbuhl, J.L. (2002) The study of mycobacterium leprae infection in interferon-γ gene—disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J. Infect. Dis., 185, 1–8.
104. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R.B. and Brooks, D.J. (2006) In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis., 21, 404–412.
105. McGeer, P.L., Itagaki, S., Akiyama, H. and McGeer, E.G. (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol., 24, 574–576.
106. Healy, D.G., Falchi, M., O’Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S. et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol., 7, 583–590.
107. Lesage, S., Durr, A., Tazir, M., Lohmann, E., Leutenegger, A.L., Janin, S., Pollak, P. and Brice, A. (2006) LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N. Engl. J. Med., 354, 422–423.
108. Ozelius, L.J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A.L., Klein, C., Henick, B., Hailpern, S.M. et al. (2006) LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N. Engl. J. Med., 354, 424–425.
109. Bar-Shira, A., Hutter, C.M., Giladi, N., Zabetian, C.P. and Orr-Urtreger, A. (2009) Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. Neurogenetics, 10, 355–358.
110. Alves-Filho, J.C., de Freitas, A., Spiller, F., Souto, F.O. and Cunha, F.Q. (2008) The role of neutrophils in severe sepsis. Shock, 30, 3–9.
111. Paula-Neto, H.A., Alves-Filho, J.C., Souto, F.O., Spiller, F., Amendola, R.S., Freitas, A., Cunha, F.Q. and Barja-Fidalgo, C. (2011) Inhibition of guanylyl cyclase restores neutrophil migration and maintains bactericidal activity increasing survival in sepsis. Shock, 35, 17–27.
112. Park, D.W., Jiang, S., Tadie, J.M., Stigler, W.S., Gao, Y., Deshane, J., Abraham, E. and Zmijewski, J.W. (2013) Activation of AMPK enhances neutrophil chemotaxis and bacterial killing. Mol. Med., 19, 387–398.
113. Kurihara, T., Jones, C.N., Yu, Y.M., Fischman, A.J., Watada, S., Tompkins, R.G., Fagan, S.P. and Irimia, D. (2013) Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J., 27, 2270–2281.
114. Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., Rice, M.E. and Yue, Z. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J. Neurosci., 30, 1788–1797.
115. Sepulveda, B., Mesias, R., Li, X., Yue, Z. and Benson, D.L. (2013) Short- and long-term effects of LRRK2 on axon and dendrite growth. PLoS One, 8, e61986.
116. Hunter, R.L., Liu, M., Choi, D.Y., Cass, W.A. and Bing, G. (2008) Inflammation and age-related iron accumulation in F344 rats. Curr. Aging Sci., 1, 112–121.
117. Bai, L., Zhang, X., Li, X., Liu, N., Lou, F., Ma, H., Luo, X. and Ren, Y. (2015) Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia. Mol. Med. Rep., 1, 1–7.
118. Fu, S.P., Wang, J.F., Xue, W.J., Liu, H.M., Liu, B.R., Zeng, Y.L., Li, S.N., Huang, B.X., Lv, Q.K., Wang, W. et al. (2015) Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson inverted question marks disease models are mediated by GPR109A-dependent mechanisms. J. Neuroinflammation, 12, 9.
119. Hritcu, L. and Gorgan, L.D. (2014) Intranigral lipopolysaccharide induced anxiety and depression by altered BDNF mRNA expression in rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry, 51, 126–132.
120. Wu, X.L., Wang, P., Liu, Y.H. and Xue, Y.X. (2014) Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson’s disease. J. Mol. Neurosci., 53, 1–9.
121. Zhang, Z., Hou, L., Song, J.L., Song, N., Sun, Y.J., Lin, X., Wang, X.L., Zhang, F.Z. and Ge, Y.L. (2014) Pro-inflammatory cytokine-mediated ferroportin down-regulation contributes to the nigral iron accumulation in lipopolysaccharide-induced Parkinsonian models. Neuroscience, 257, 20–30.
122. Ailane, S., Long, P., Jenner, P. and Rose, S. (2013) Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra. Eur. J. Neurosci., 38, 2468–2476.
123. Golembiowska, K., Wardas, J., Noworyta-Sokolowska, K., Kaminska, K. and Gorska, A. (2013) Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson’s disease. Neurotox. Res., 24, 29–40.
124. Hoban, D.B., Connaughton, E., Connaughton, C., Hogan, G., Thornton, C., Mulcahy, P., Moloney, T.C. and Dowd, E. (2013) Further characterisation of the LPS model of Parkinson’s disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav. Immun., 27, 91–100.
125. Chung, E.S., Bok, E., Chung, Y.C., Baik, H.H. and Jin, B.K. (2012) Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase. Brain Res., 1451, 110–116.
126. Ji, K.A., Eu, M.Y., Kang, S.H., Gwag, B.J., Jou, I. and Joe, E.H. (2008) Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia, 56, 1039–1047.
127. Weatherly, D.B., Atwood, J.A. 3rd, Minning, T.A., Cavola, C., Tarleton, R.L. and Orlando, R. (2005) A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol. Cell Proteomics, 4, 762–772.
128. Nesvizhskii, A.I., Keller, A., Kolker, E. and Aebersold, R. (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem., 75, 4646–4658.
129. Keller, A., Nesvizhskii, A.I., Kolker, E. and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem., 74, 5383–5392.
130. Liu, H., Sadygov, R.G. and Yates, J.R. 3rd (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem., 76, 4193–4201.
131. Old, W.M., Meyer-Arendt, K., Aveline-Wolf, L., Pierce, K.G., Mendoza, A., Sevinsky, J.R., Resing, K.A. and Ahn, N.G. (2005) Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell Proteomics, 4, 1487–1502.
132. Beissbarth, T., Hyde, L., Smyth, G.K., Job, C., Boon, W.M., Tan, S.S., Scott, H.S. and Speed, T.P. (2004) Statistical modeling of sequencing errors in SAGE libraries. Bioinformatics, 20, 31–39.
133. Webber, P.J., Smith, A.D., Sen, S., Renfrow, M.B., Mobley, J.A. and West, A.B. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol., 412, 94–110.